ESR1 and breast carcinoma: For hormone receptor-positive/HER2-negative subtype, which accounts for a large proportion of breast cancer, endocrine therapy (ET), including aromatase inhibitors (AIs), selective ER modulators (SERMs), and selective ER down-regulators (SERDs), is the bedrock (3, 4).